Hepatic expression of iron-related genes in patients with PCT compared with patients with hh
| Patient . | HFE* . | HepC . | EtOH . | HPCSI . | HAMP . | SMAD4 . | NEO . | FPN . | HJV . | TFR2 . | TFR1 . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | C,Y | + | 3 | 3 | −9.47 | −1.06 | −1.16 | 1.01 | −1.07 | −1.05 | 2.04 |
| 2 | C,C | + | 2 | 3 | −10.25 | −1.19 | −1.06 | 1.24 | −1.03 | 1.19 | 4.42 |
| 3 | C,C | − | 1 | 1 | −1.37 | −1.06 | −1.28 | −1.01 | 1.08 | 1.41 | 1.29 |
| 4 | C,C | + | 3 | 2 | −2.73 | −1.07 | −1.19 | 1.02 | 1.06 | −1.09 | 1.24 |
| 5 | Y,Y | − | 2 | 4 | −1.20 | −1.90 | −1.18 | 1.19 | −1.07 | −1.04 | −1.16 |
| 6 | C,C | + | 3 | 2 | −1.03 | −1.07 | 1.11 | 1.10 | 1.01 | 1.06 | 1.35 |
| 7 | C,C | − | 3 | 3 | −1.85 | 1.15 | 1.21 | 1.14 | −1.09 | −1.06 | −1.17 |
| 8† | C,C | − | 3 | 2 | 1.26 | −1.27 | −1.29 | −1.08 | 1.16 | −1.06 | −1.49 |
| 9 | C,Y | − | 0 | 3 | 1.69 | 1.04 | −1.00 | 1.06 | 1.01 | −1.03 | 1.09 |
| 10 | C,C | − | 2 | 2 | 1.21 | 1.95 | −1.00 | 1.06 | 1.44 | 1.18 | −1.08 |
| 11 | C,Y | − | 0 | 1 | −1.46 | 1.04 | 1.01 | −1.13 | −1.01 | −1.04 | −1.30 |
| 12 | C,Y | − | 0 | 1 | −1.96 | −2.18 | −1.24 | −1.58 | 1.07 | 1.26 | 1.37 |
| 13 | Y,Y | − | 0 | 2 | −9.02 | 1.51 | −1.11 | −1.20 | −1.31 | 1.14 | 2.63 |
| 14 | C,C | − | 0 | 1 | −1.71 | −2.54 | −1.16 | 1.04 | −1.21 | −1.11 | 1.30 |
| Patient . | HFE* . | HepC . | EtOH . | HPCSI . | HAMP . | SMAD4 . | NEO . | FPN . | HJV . | TFR2 . | TFR1 . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | C,Y | + | 3 | 3 | −9.47 | −1.06 | −1.16 | 1.01 | −1.07 | −1.05 | 2.04 |
| 2 | C,C | + | 2 | 3 | −10.25 | −1.19 | −1.06 | 1.24 | −1.03 | 1.19 | 4.42 |
| 3 | C,C | − | 1 | 1 | −1.37 | −1.06 | −1.28 | −1.01 | 1.08 | 1.41 | 1.29 |
| 4 | C,C | + | 3 | 2 | −2.73 | −1.07 | −1.19 | 1.02 | 1.06 | −1.09 | 1.24 |
| 5 | Y,Y | − | 2 | 4 | −1.20 | −1.90 | −1.18 | 1.19 | −1.07 | −1.04 | −1.16 |
| 6 | C,C | + | 3 | 2 | −1.03 | −1.07 | 1.11 | 1.10 | 1.01 | 1.06 | 1.35 |
| 7 | C,C | − | 3 | 3 | −1.85 | 1.15 | 1.21 | 1.14 | −1.09 | −1.06 | −1.17 |
| 8† | C,C | − | 3 | 2 | 1.26 | −1.27 | −1.29 | −1.08 | 1.16 | −1.06 | −1.49 |
| 9 | C,Y | − | 0 | 3 | 1.69 | 1.04 | −1.00 | 1.06 | 1.01 | −1.03 | 1.09 |
| 10 | C,C | − | 2 | 2 | 1.21 | 1.95 | −1.00 | 1.06 | 1.44 | 1.18 | −1.08 |
| 11 | C,Y | − | 0 | 1 | −1.46 | 1.04 | 1.01 | −1.13 | −1.01 | −1.04 | −1.30 |
| 12 | C,Y | − | 0 | 1 | −1.96 | −2.18 | −1.24 | −1.58 | 1.07 | 1.26 | 1.37 |
| 13 | Y,Y | − | 0 | 2 | −9.02 | 1.51 | −1.11 | −1.20 | −1.31 | 1.14 | 2.63 |
| 14 | C,C | − | 0 | 1 | −1.71 | −2.54 | −1.16 | 1.04 | −1.21 | −1.11 | 1.30 |
Up-regulated samples are in normal font; down-regulated samples are in bold font. Hepatitis C (HepC), hepcidin (HAMP), homolog to sma and mad (SMAD), neogenin (NEO), ferroportin (FPN), hemojuvelin (HJV), transferrin receptor 2 (TFR2), transferrin receptor 1 (TFR1).
Residue at position 282 in the HFE protein (C indicates cys; and Y, tyr).
F-PCT.